Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
XENE
#1349
Xenon Pharmaceuticals Inc
43.230
0
-2.43%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
-2.43%
Changement Mensuel
+1.98%
Evolution sur 6 mois
+5.98%
Changement Annuel
+5.98%
Clôture Précédente
44.305
0
Open
43.250
0
Bid
Ask
Low
43.230
0
High
43.250
0
Volume
189
Marchés
Actions des Marchés US
Soins de Santé
XENE
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
76.24 M
76.54 M
76.73 M
77.11 M
77.28 M
83.19 M
—
Valuation ratios
Enterprise value
2.91 B
2.86 B
2.46 B
2.28 B
3 B
3.53 B
11.26 B
Price to earnings ratio
-13.91
-13.02
-10.42
-8.84
-10.35
-10.28
-39.89
Price to sales ratio
-4 810.07
2 869.8
314.03
293.33
387.33
—
—
Price to cash flow ratio
-19.49
-16.83
-13.4
-10.66
-12.53
12.73
-23.87
Price to book ratio
0.85
4.04
0.84
0.85
1.19
6.11
8.99
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.08
0.08
0.09
0.13
0.15
0.17
0.53
Return on equity %
0.08
0.09
0.09
0.13
0.16
0.18
0.57
Return on invested capital %
175.09
173.41
168.35
211.02
251.05
435.01
1 065.43
Gross margin %
100
100
100
—
—
—
—
Operating margin %
31.09 K
11.92 K
969.84
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
26.49 K
10.11 K
867.29
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
22.21
17.85
17.66
15.14
12.52
13.42
58.73
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0
0.01
0
0
0
0.01
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.64
0.7
0.78
0.81
0.91
1.03
3.53
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
8.39
8.05
6.98
6.18
5.83
6.93
25.92
Net current asset value per share
8.46
8.16
7.19
6.34
6.06
7.07
26.66
Tangible book value per share
10.24
9.69
8.95
8.03
7.06
7.34
31.38
Working capital per share
8.08
7.7
6.78
5.92
5.57
6.55
24.82
Book value per share
10.24
9.69
8.95
8.03
7.06
7.34
31.38
Nouvelles
Alibaba Earnings, Jobs Data
L’action Xenon Pharmaceuticals atteint un sommet de 52 semaines à 46,68$
Xenon Pharmaceuticals stock hits 52-week high at $46.68
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
Les résultats de Xenon approchent alors que les investisseurs se préparent au catalyseur de Phase 3
Xenon earnings loom as investors brace for Phase 3 catalyst
Wolfe Research initie la couverture de Xenon Pharmaceuticals avec une note de surperformance
Wolfe Research initiates Xenon Pharmaceuticals stock coverage with outperform rating
Xenon Pharmaceuticals Stock Scores RS Rating Upgrade
Stifel relève l’objectif de cours de Xenon Pharmaceuticals à 66$ sur le potentiel de XEN1101
Stifel raises Xenon Pharmaceuticals stock price target to $66 on XEN1101 potential
Biohaven stock rating upgraded by RBC Capital on promising CNS data